Advanced Cancers
Conditions
Keywords
Advanced cancer, Advanced Cancer with genetic mutation, Phosphoinositides 3-kinase, PI3K, PIK3 mutations, Temsirolimus, CCI-779, Torisel, mTOR inhibitor
Brief summary
The goal of this clinical research study is to learn if temsirolimus can help to control advanced cancer in patients who also have a PI3K mutation and/or PTEN loss. The safety of this drug will also be tested.
Detailed description
The Study Drug: Temsirolimus is designed to block the growth of cancer cells, which may cause the cancer cells to die. Study Drug Administration: If you are found to be eligible to take part in this study, you will receive temsirolimus through a needle in your vein on Days 1, 8, 15, and 22 of each 4-week study cycle. On Day 1 of Cycle 1, the study drug will be given over 60 minutes. If you tolerate the study drug well on Day 1 of Cycle 1, it will be given over 30 minutes at all other scheduled administration dates as long as you still tolerate it well. If the dose is not well tolerated, the dose will be reduced for future study visits. You will receive Benadryl (diphenhydramine) or a similar drug by vein to help prevent side effects about 30 minutes before you receive the study drug. Study Visits: One (1) time each week (on each day that the study drug is being given), the following tests and procedures will be performed: * Your weight and vital signs will be measured. * You will be asked about any drugs you may be taking and about any side effects you may be having. * Blood (about 2 teaspoons each time) will be drawn for pharmacodynamic (PD) testing. PD testing measures how the level of study drug in your body may affect the disease. This blood will be drawn at the following times: At 8 hours (+/- 3 hours) after the dose At 24 hours (+/- 3 hours) after the dose At 72 hours (+/- 24 hours) after the dose Every 2 weeks, blood (about 2 teaspoons) will be drawn for routine tests. Every 4 weeks, you will have a physical exam; women who are able to become pregnant will also have a blood (about 1 teaspoon) pregnancy test. Every 8 weeks, you will have a CT scan, MRI scan, and/or PET/CT scan to check the status of the disease. Length of Study: You will be on study for as long as you are benefiting or the disease is stable. You will be taken off study if the disease gets worse, you have intolerable side effects, or the study doctor thinks it is in your best interest. End-of-Study Visit: After you have finished taking the study drug, the following tests and procedures will be performed: * You will have a physical exam, including measurement of your weight and vital signs. * You will be asked about any drugs you may be taking and about any side effects you may be having. This is an investigational study. Temsirolimus is FDA-approved and commercially available for the treatment of advanced renal cancer. Its use in other types of cancer is investigational. Up to 65 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
DRUGTemsirolimus
25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with pathologically confirmed advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or has no standard therapy that improves survival by at least 3 months (unless temsirolimus is indicated as standard treatment for that disease). 2. Patients must have evaluable tumor(s) with documented PIK3 mutation and/or PTEN loss. 3. Patients must have creatinine \</= 3 X upper limit of normal (ULN); absolute neutrophil count \>/= 1,000/mL; platelets \>/= 50,000; bilirubin \</= 3.0 gm/dL. Except for patients with liver metastases: total bilirubin \</= 5 ULN. 4. Women of childbearing potential must have a negative baseline blood pregnancy test. Women and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study. 5. Patients must be off other anti-tumor agents for at least 5 half lives of the agent or 4 wks from the last day of treatment, whichever is shorter. For cytotoxic therapies, patients should be off treatment for 3 or more weeks. 6. Patients may not be receiving any other experimental agents that are not FDA approved. 7. Ability to understand and willingness to sign a written consent document. 8. Treatment on this study may begin within 24 hours after Phase 0 dose of Temsirolimus.
Exclusion criteria
1. Pregnant or lactating women. 2. Patients with creatinine clearance \<10 mL/min 3. Patients with a known hypersensitivity to any of the components or metabolites of the drug products. 4. Patients with major surgery within 30 days prior to entering study. 5. Patients on inhibitors or inducers of CYP3A4 metabolism will have the inhibitors or inducers stopped unless clinically contraindicated. See section 6 (Concomitant Medications) and Appendix E of the protocol for details.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response | Baseline to Disease Progression (restaged at 8 weeks and at 4 months) | For solid tumors, initial responses defined by Response Evaluation Criteria in Solid (RECIST) criteria in the evaluable lesion(s) per Complete Response (CR): Disappearance of all target lesions; confirmed at 4 weeks; Partial Response (PR): At least 30% decrease; confirmed at 4 weeks; Stable Disease (SD): Neither PR nor PD criteria met; Progressive Disease (PD): 20% increase; no CR, PR or SD documented before increased disease, or new lesion(s). |
Countries
United States
Participant flow
Recruitment details
Recruitment Period: April 6, 2009 to March 28, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.
Participants by arm
| Arm | Count |
|---|---|
| Temsirolimus Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle. | 44 |
| Total | 44 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Disease Progression | 44 |
Baseline characteristics
| Characteristic | Temsirolimus |
|---|---|
| Age, Continuous | 57 years |
| Region of Enrollment United States | 44 participants |
| Sex: Female, Male Female | 25 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 19 / 44 |
| serious Total, serious adverse events | 6 / 44 |
Outcome results
Primary
Tumor Response
For solid tumors, initial responses defined by Response Evaluation Criteria in Solid (RECIST) criteria in the evaluable lesion(s) per Complete Response (CR): Disappearance of all target lesions; confirmed at 4 weeks; Partial Response (PR): At least 30% decrease; confirmed at 4 weeks; Stable Disease (SD): Neither PR nor PD criteria met; Progressive Disease (PD): 20% increase; no CR, PR or SD documented before increased disease, or new lesion(s).
Time frame: Baseline to Disease Progression (restaged at 8 weeks and at 4 months)
Population: Of the 44 participants enrolled, only 30 were evaluable for response.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Temsirolimus | Tumor Response | Progressive Disease (PD) | 8 participants |
| Temsirolimus | Tumor Response | Complete Response (CR) | 0 participants |
| Temsirolimus | Tumor Response | Partial Response (PR) | 2 participants |
| Temsirolimus | Tumor Response | Stable Disease | 20 participants |